Related Experiment Video
Updated: Jan 8, 2026
Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
Published on: August 22, 2012
Public Health
Marwan N Sabbagh1, Sharon Cohen2, Ashley Holub3
1Barrow Neurological Institute, Phoenix, AZ, USA.
Background:
Although both anti-amyloid monoclonal antibodies have demonstrated slowed disease progression in mild cognitive impairment and mild dementia due to Alzheimer's disease, lecanemab and donanemab have different mechanisms of action and, consequently, safety profiles. This study conducted indirect treatment comparisons (ITCs) of ARIA outcomes and death to understand safety differences.
Method:
This ITC utilized ARIA rates in the FDA-approved labels, FDA review documents, or peer-reviewed publications. Outcomes included ARIA with edema/effusions (ARIA-E), ARIA with microhemorrhage or superficial siderosis (ARIA-H), intracerebral hemorrhage (ICH, ≥1cm), APOE4 status, all-cause death, and other ARIA outcomes in the overall clinical trial population over 18 months. Anchored Bucher ITCs were used to compare rates of ARIA outcomes between lecanemab and donanemab, leveraging placebo as the common comparator. Risk difference-in-difference (RDD), 95% confidence intervals (CI), and p-values for normal distribution comparing treatments were derived.
Result:
Lecanemab demonstrated significantly lower risk of any ARIA compared to donanemab (ARIA-E or ARIA-H) with a RDD of -10.1% (95% CI: [-15.3%, -5.0%]). Similarly, the RDD for ARIA-E (-10.7% [-14.5%, -6.9%]) and ARIA-H (-10.1% [-15.0%, -5.2%]), were also significantly lower. Among APOE4 carriers, these differences persisted for ARIA-E (-11.1% [-16.0%, -6.2%]), and ARIA-H (-14.4% [-20.5%, -8.2%]). Lecanemab also had significantly lower risk of microhemorrhage (-7.5% [-12.1%, -2.9%]), and superficial siderosis (-8.8% [-12.0%, -5.6%]). Incidence of ICH (0.3% [-0.5%, 1.1%]) and death (-1.0% [-2.4%, 0.5%]) were not significantly different between treatments. Lecanemab demonstrated significantly lower risk of death with concurrent ARIA or ICH (-0.5%, [-0.9%, 0.0%]) compared to donanemab.
Conclusion:
Lecanemab demonstrated significantly lower risks of ARIA outcomes overall and in subgroups of interest compared to donanemab, including death related to ARIA or ICH, in ITC analysis. Future research understanding comparative safety profiles in real-world settings may inform treatment decisions.
More Related Videos
09:33Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
Published on: December 23, 2022
07:20Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Related Concept Videos
01:30Primary Healthcare Services
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
01:26Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
01:30Preventive Healthcare Services
01:26Principles of Disease Surveillance
01:17Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...